Financial Results
Choksi Asia Publishes Q2 FY27 Results
Choksi Asia published newspaper extracts of unaudited financial results for the quarter and half year ended September 30, 2026.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
5
Neutral
4
Bullish
5
Bearish
32
Neutral
4
Bullish
10
Bearish
27
Neutral
0
Bullish
5
Bearish
27
Neutral
0
Bullish
5
Bearish
27
Neutral
0
Bullish
5
Bearish
27
Neutral
0
Bullish
5
Financial Results
Choksi Asia published newspaper extracts of unaudited financial results for the quarter and half year ended September 30, 2026.
Financial Results
Choksi Asia approved standalone unaudited results for the quarter and half year ended September 30, 2026, reporting quarterly net profit of ₹106.06 lakh.
Choksi Asia Ltd (CHOKSI) is currently trading at 196.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Choksi Asia Limited is a family-promoted manufacturer of photosensitised materials and imaging consumables, producing X-ray films and photographic colour paper, trading contrast media, X-ray accessories and processors, and servicing healthcare and industrial radiography customers across India under the Choksi Asia corporate umbrella. Financials for quarter ended June 30, 2026 show revenue from operations at 922.10 and total income of 950.88, with Profit Before Tax at 154.08 and Net Profit After Tax at 96.17; notable dynamics include a meaningful sequential revenue decline versus the prior quarter and an improved reported net profit, producing EPS of 1.69 on paid-up capital of 570.11. Operationally the quarter exhibits a large positive change in inventories (311.18) alongside a sharp reduction in purchases of stock-in-trade (196.21 versus 418.49 prior quarter) and lower other expenses, indicating inventory and working-capital adjustments that materially affected margins and profitability in the quarter. Corporate restructuring remains a recent strategic headline: Choksi Asia Limited completed an amalgamation in 2024-25 and updated its object clause and name in 2025, a clear corporate-level change intended to align the enlarged group's scope and pursue synergies across imaging products and trading operations.
Over the past 52 weeks, Choksi Asia Ltd has traded between a low of ₹103.00 and a high of ₹266.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Choksi Asia Ltd has a market capitalization of approximately 112.63. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Choksi Asia Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 22.99 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 112.63 Cr, Choksi Asia Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Choksi Asia Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Choksi Asia Ltd is 22.99. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Healthcare Equipment & Supplies
Medical Equipment & Supplies
113 Cr
Moderate Risk
23.0
60.1
0.3
2.9
266.45
103.00
Sales CAGR
Profit CAGR
ROE
ROCE
